26 November 2021
Top in Tech: Technology Demonstration Library
Discover the latest technologies for advanced therapies with this library of short demonstrations, brought to you by the experts.
Top in Tech: Technology Demonstration Library
Discover the latest technologies for advanced therapies with this libr
Scaling Up Development and Manufacturing at Speed: Meeting the Challenge of a Pandemic Response
Webinar
Standard member
Adapting Products to the Unique and Evolving Needs of the CGT Industry with OriGen Biomedical
Tech Demo
Standard member
Watch On-Demand
Latest Podcast Episodes
People and ideas that inspire the advanced therapies industry
Content services
Your Content Marketing Agency for Advanced Therapies
From creation to distribution, Phacilitate is a full service content marketing agency
Our eBooks & Infographics
A snapshot of the industry’s approach to commercialisation, presented as a handy infographic.
A collection of the outcomes from the roundtables and panels that took place at Advanced Therapies Connect 2020
This e-book examines 15 of the world’s leading immuno-oncology biotechnology companies, providing you with an at-a-glance view plus more detailed information on how their pipelines are developing.
2017 was a milestone year for the immuno-oncology industry. There was big headline news; Novartis’ Kymriah and Kite’s submission of their ZUMA-1 trial to European regulators, as well as numerous incremental wins.
The pace of innovation across cell and gene therapy biotechs is gaining speed and it can be challenging to keep track of scientific developments, new technologies and who might be looking for their next big partnership.
A guide to the non-dilutive funding applications that are open or opening soon from the US and Europe.
What are the key commercialisation challenges associated with bringing a cell and/or gene therapy to a commercial scale?
This eBook, created in partnership with Bio-Techne, explores the anticipated challenges to the industry’s growing commercialisable pipeline, as well as the way in which those challenges may be considered unique to advanced therapy medicinal products (ATMPs).
